GUIDELINE REVIEW
Hypercholesterolaemia in children guidelines review
1 Plymouth, UK
2 Bristol Royal Hospital for Children, Bristol, UK
Correspondence to:
J H Baumer; harry@luson.plus.com
| The first 150 words of the full text of this article appear below. |
Familial hypercholesterolaemia (FH) is an important autosomal dominant cause of early-onset atheroma and coronary artery disease. Most affected individuals are heterozygotes, with an estimated population frequency of 1 in 500, and have one affected parent. Much more rarely, children may be homozygous, with an estimated frequency of 1 in a million, and with two affected parents. The development of more effective treatments for this condition have raised questions about the optimum timing of initiation of treatment and therefore of targeted investigations in children.
In addition, the rising rate of obesity in adults and children is associated with an increasing risk of cardiovascular disease in those without a family history of hypercholesterolaemia. Early identification of those children with both obesity and raised cholesterol levels could help to modify subsequent cardiovascular risk. In the USA, the American Academy of Pediatrics (AAP) has updated its guidance on cholesterol in childhood.1 It advocates including
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.



